$5.95
2.46%
Nasdaq, Nov 19, 03:58 pm EST. Closed.
ISIN
NL0015285941
Symbol
IMTX

Immatics N.V Stock price

$5.95
-1.10 15.60% 1M
-4.75 44.39% 6M
-4.55 43.33% YTD
-4.38 42.40% 1Y
-2.64 30.73% 3Y
-5.94 49.96% 5Y
-3.65 38.02% 10Y
-3.65 38.02% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
-0.15 2.46%
ISIN
NL0015285941
Symbol
IMTX
Industry

AI Insights on Immatics N.V Insights AI Insights on Immatics N.V

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Immatics N.V a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$912.8m
Enterprise Value
$497.1m
Net debt
positive
Cash
$431.5m
Shares outstanding
136.7m
Valuation
P/E
negative
P/S | estimate
19.9 | 21.6
EV/Sales | estimate
10.9 | 11.8
EV/FCF | ex SBC
negative | negative
P/B
2.1
Financial Health
Equity Ratio
86.1%
Return on Equity
-40.6%
ROCE
-52.9%
ROIC
-330.0%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$19.2m | 42.0%
SBC as % of FCF
-
SBC Growth 1Y
0.1%
Share Count Growth 1Y
12.4%
Shareholder Yield
-12.4%
Financials
Revenue | estimate
$45.8m | $42.2m
EBITDA
$-235.7m
EBIT
$-248.9m
Net Income
$-226.7m
Free Cash Flow | ex SBC
$-230.1m | $-249.3m
Growth
Revenue | estimate
-68.0% | -20.4%
EBITDA
-187.1%
EBIT
-160.4%
Net Income
-179.5%
Free Cash Flow
-20.0%
Margin
Gross
-
EBITDA
-515.0%
EBIT
-543.8%
Net
-495.3%
Free Cash Flow | ex SBC
-502.6% | -544.6%
More
EPS
$-1.7
FCF per Share
$-1.7
Short interest
3.3%
Employees
650
Rev per Employee
$80.0k

Immatics N.V Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Immatics N.V forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Immatics N.V forecast:

Buy
94%
Hold
6%

Financial data from Immatics N.V

Jun '26
+/-
%
46 46
68% 68%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 60 60
11% 11%
131%
- Research and Development Expense 240 240
30% 30%
524%
-236 -236
187% 187%
-515%
- Depreciation and Amortization 13 13
2% 2%
29%
EBIT (Operating Income) EBIT -249 -249
160% 160%
-544%
Net Profit -227 -227
179% 179%
-495%

In millions USD.

Don't miss a Thing! We will send you all news about Immatics N.V directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immatics N.V Stock News

Neutral
GlobeNewsWire
●
10 days ago
Houston, Texas and Tuebingen, Germany, November 10, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today provided a business update and reported financial results for the quarter ended September 30, 2026.
Neutral
GlobeNewsWire
●
27 days ago
Houston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated clinical trial data from its ongoing Phase 1b study with IMA402 PRAME bispecific and its Phase 1 study with IMA203CD8 PRAME cel...
Neutral
GlobeNewsWire
●
3 months ago
Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced today that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funde...
More Immatics N.V News

Company Profile

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.

Head office Netherlands
CEO Dr. Singh
Employees 650
Founded 2020
Website immatics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today